Patient | Hunt+Hess | Fisher score | Aneurysm location | Neck width | Dome width | Dome/neck ratio | Endoventricular drain | Before medication | After medication | Intraoperative complications | Immediate postoperative mRRC | First follow-up (months) | Radiographic outcome at delayed follow-up (mRRC) | Final mRS |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | IV | IV | Basilar tip | 7.2 | 13.5 | 1.87 | Y—pre-op | 500 ASA IV, 600 clopidogrel p.o. | Clopidogrel | No | IIIb | 2 | Stable neck remnant (IIIb) | 1 |
2 | V | IV | AcomA | 6.1 | 8.5 | 1.4 | Y—pre-op | 2×500 mg ASA IV | Clopidogrel | No | IIIb | Dead | Dead | 6 |
3 | IV | IV | Basilar tip | 11.1 | 14.4 | 1.3 | Y—pre-op | 500 ASA IV, 300 clopidogrel p.o. | Clopidogrel | No | IIIb | Dead | Dead | 6 |
4 | IV | IV | Basilar tip | 4.4 | 5.1 | 1.16 | Y—pre-op | 2×500 ASA IV, 600 clopidogrel p.o. | Clopidogrel | No | I | Dead | Dead | 6 |
5 | II | IV | Right MCA | 10.6 | 13.2 | 1.24 | Y—pre-op | 500 ASA IV, 300 clopidogrel p.o. | Clopidogrel | No | IIIb | 2 | Compaction and growth (IIIb)—re-treatment | 0 |
6 | IV | IV | AcomA | 3 | 3.2 | 1.06 | Y—pre-op | 500 ASA IV, 600 clopidogrel p.o. | Clopidogrel | Thrombus in A1 | I | 3 | Complete occlusion (I) | 0 |
7 | II | III | AcomA | 4.4 | 6 | 1.36 | N | ASA IV, clopidogrel p.o. and eptifibatide IV | Clopidogrel | No | I | 6 | Complete occlusion (I) | 1 |
8 | II | IV | BA fenestration | 9.6 | 13.4 | 1.4 | Y—pre-op | ASA IV, clopidogrel p.o. and eptifibatide IV | Clopidogrel | No | II | Dead | Dead | 6 |
9 | III | IV | Basilar tip | 7.8 | 11.1 | 1.42 | Y—pre-op | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | I | 4 | Complete occlusion (I) | 1 |
10 | I | III | Right MCA | 8.5 | 11.9 | 1.4 | N | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | IIIb | 3 | Stable neck remnant (IIIb) | 0 |
11 | I | II | AcomA | 6.25 | 8.03 | 1.28 | N | Loading ASA IV and ticagrelor p.o. | Brilique | No | I | 3 | Small neck recurrence (II) | 0 |
12 | I | II | Basilar tip | 5.52 | 8.2 | 1.48 | N | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | I | 3 | Complete occlusion (I) | 0 |
13 | II | IV | Basilar tip | 5.3 | 10.7 | 2 | Y—pre-op | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | I | 5 | Coil compaction + small neck recurrence (II)—re-treatment | 0 |
14 | V | IV | Basilar tip | 5.5 | 6.3 | 1.14 | Y—pre-op | ASA IV, ticagrelor p.o. and eptifibatide IV | Clopidogrel | No | I | 7 | Complete occlusion (I) | 0 |
15 | III | IV | AcomA | 5.5 | 14.6 | 2.65 | Y—pre-op | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | IIIa | 9 | Complete occlusion (I) | 2 |
16 | I | I | Basilar tip | 7.76 | 9.2 | 1.18 | N | Loading ASA IV and ticagrelor p.o. | Brilique | No | IIIb | 2 | Complete occlusion (I) | 2 |
17 | III | III | Left MCA | 5 | 4 | 0.8 | N | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | II | 2 | Stable neck remnant (II)—re-treatment | 1 |
18 | I | I | Right MCA | 3 | 3.4 | 1.13 | N | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | II | 3 | Complete occlusion (I) | 1 |
19 | I | I | AcomA | 8.5 | 14.1 | 1.66 | N | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | Perforation+thrombus | II | 3 | Neck recurrence | 0 |
20 | I | I | AcomA | 4 | 7 | 1.75 | N | ASA IV, ticagrelor p.o. and eptifibatide IV | Brilique | No | I | 3 | Complete occlusion (I) | 0 |
21 | I | III | Pericallosal | 6 | 12 | 2 | N | ASA IV, ticagrelor p.o. and eptifibatide IV | Aspirin and Brilique | IIIb | None yet | None yet | N/A |
AcomA, anterior communicating artery; ASA, acetylsalicylic acid; BA, Basilar artery; MCA, middle cerebral artery; mRCC, modified Raymond–Roy classification; mRS, modified Rankin Scale